Tumor cells may bypass VEGFR inhibition by upregulating compensatory pro-angiogenic pathways such as the FGF/FGFR axis or hepatocyte growth factor (HGF)/c-MET signaling [31,90]. The gene discussed is KDR; the disease is neoplasm.